Eli Lilly gained exclusive, worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound for $87 million. BioMS also stands to earn development and sales milestones of up to $410 million. The company will receive escalating royalties.
MBP8298 is currently in two Phase III trials in secondary progressive MS and one Phase II study in relapsing-remitting MS. Under the terms of the agreement, Lilly and BioMS Medical will collaborate on the development of MBP8298. The firms will share some development costs, with Lilly being responsible for future R&D, manufacturing, and marketing activities.